

## PHARMACY PRE-AUTHORIZATION CRITERIA



Drug (s)	Ravicti (glycerol phenylbutyrate)
Policy#	23108
Indications	Ravicit is indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients ≥2 months of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements).
CRITERIA	<ul> <li>Connecticare considers Ravicti to be medically necessary when all of the following are met:</li> <li>The patient has been seen by a geneticist/metabolic specialist and nutritionist</li> <li>The patient has a diagnosis of urea cycle disorder (UCD)</li> <li>The patient has documentation of a protein restrictive diet</li> <li>There has been a failure to control ammonia level</li> </ul>
REFERENCES	Ravicti full prescribing information. San Francisco, CA. Hyperion Therapeutics.
P&T REVIEW HISTORY	10/13, 10/14, 11/15, 2/16, 8/17, 7/18
REVISION RECORD	8/17, 2/19